在全身性红斑狼中,ELF1作为疾病活动和脏参与的潜在生物标志物
Yukun Zhang1,2, Minglong Cai3, Xiaoyi Huang1
1Department of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei, 230032, Anhui, China.
Scientific reports
|November 4, 2024
概括
这项研究确定了ELF1作为系统性红斑狼 (SLE) 的潜在生物标志物. 在T细胞中较低的ELF1基因表达与SLE诊断和疾病严重程度相关,提供新的诊断和治疗途径.
科学领域:
- 遗传学 遗传学 是一个
- 免疫学 免疫学 免疫学
- 生物标志物发现发现
背景情况:
- 系统性红斑狼 (SLE) 是一种复杂的自身免疫性疾病,其机制不清楚,缺乏特定的生物标志物.
- 识别新的遗传因素和可靠的生物标志物对于改善SLE诊断和管理至关重要.
研究的目的:
- 通过使用遗传关联和表达数据,识别与SLE相关的新功能基因.
- 研究SLE患者中已识别的基因,特别是ELF1的诊断和预后潜力.
主要方法:
- 利用孟德尔的随机化和HEIDI分析对大规模的全基因组协会研究 (GWAS) 和表达量化特征位置 (eQTL) 数据.
- 分析了来自SLE患者和健康对照者的CD4+T细胞中的ELF1基因表达.
- 在SLE亚组中,与临床参数和疾病活性评分 (SLEDAI) 相关联的ELF1表达.
- 执行接收器操作特征 (ROC) 曲线分析,以评估诊断和预后效用.
主要成果:
- 确定了七种与SLE相关的新型潜在功能基因:BLK,ELF1,STIM1,B3GALT6,APOLD1,INPP5B和FHL3.
- 与对照组相比,SLE患者的CD4+T细胞中发现ELF1基因表达显著降低.
- 在SLE亚组中观察到ELF1表达的下降趋势,以及疾病活性和严重性的指标.
- 在SLE中表达ELF1的强烈诊断潜力 (AUC=0.9493),以及评估疾病活性 (AUC=0.6852) 和脏参与 (AUC=0.7363) 的实用性.
结论:
- ELF1基因表达作为SLE诊断和疾病活性评估的有前途的生物标志物.
- 这些发现提供了对SLE病变的洞察力,并突出了ELF1作为潜在的治疗点.
- 对ELF1作用的进一步研究可以推进SLE诊断和治疗策略.
相关概念视频
Ultrasound II: Endoscopic Ultrasound and FibroScan
80
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
80
Factors Affecting Renal Clearance: Renal Impairment
57
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
57
Renal Failure: Dose Adjustments
67
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
67


